Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P980023/S153

Ilivia Neo 7 VRT DX, Intica Neo 7 VRT DX, Intica Neo 5 VRT DX, Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Ri

Biotronik, Inc. · Decision date Oct 22, 2026

MEDTECHLEDGER EXPLANATIONP980023/S153

What did the FDA decide?

Biotronik, Inc. holds PMA P980023/S153, a 30-Day Notice recorded with decision OK30 on 2026-10-22. The supplement covers a process change attributed to manufacturer, sterilizer, packager or supplier, described as updating visual and dimensional incoming inspection testing for certain components and raw materials used in IPG, ICD and lead manufacturing. The listed products include Ilivia Neo and Intica Neo VRT DX, Acticor Sky VR-T, Rivacor Sky and Rivacor Rise VR-T devices, categorized as non-CRT implantable cardioverter defibrillators under product code LWS, Cardiovascular specialty.

The record does not identify which components or raw materials are affected, what the prior inspection criteria were, or the revised acceptance limits, so the operational effect on manufacturing cannot be assessed from this entry. OK30 is the recorded decision for this supplement; it is not a new approval of the underlying system, and no clinical, efficacy or patient-selection conclusions follow from the notice. The title field is truncated in the source, leaving the full device list unknown.

Whether the revised inspection changes defect detection or supply risk for these ICDs and leads is not stated in the available data.

FDA approval order statement

updating visual and dimensional incoming inspection testing for certain components and raw materials used in IPG, ICD, and lead manufacturing
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 22, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P980023/S153
Regulatory pathway
PMA supplement
Product code
LWS
Decision code
OK30
Decision date
Oct 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

For the original device and its historical approval scope, see PMA P980023. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P980023 · Original PMA

    PHYLAX IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SYSTEM

  2. P980023/S150 · Related supplement

    Pamira S 60; Pamira S 65; Pamira S 75; Pamira SD 60/16; Pamira SD 65/16; Pamira SD 65/18; Pamira SD 75/18; Pamira S DX 6

  3. P980023/S146 · Related supplement

    Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva

  4. P980023/S153 received

    Application receipt date recorded by FDA.

  5. P980023/S140 · Related supplement

    Ilivia Neo 7 VR-T DX 429530; Intica Neo 7 VR-T DX 429559; Intica Neo 5 VR-T DX 429569

  6. P980023/S151 · Related supplement

    Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva

  7. P980023/S149 · Related supplement

    Acticor Sky VR-T 481989; Rivacor Sky VR-T 481984; Rivacor Rise VR-T 482020; Rivacor Aura VR-T 482015; Acticor Sky VR-T D

  8. P980023/S152 · Related supplement

    Ilivia Neo 7 VR-T DX DF-1 ProMRI, Ilivia Neo 7 VR-T DF-1 ProMRI, Intica Neo 7 VR-T DX DF-1 ProMRI, Intica Neo 7 VR-T DF-

  9. P980023/S153 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P980023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P980023

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records